MiniPlus

MiniPlus

Miniplus is a brand of antihypertensive (prazosin Hydrochloride and Hydrochlorothiazide in combination). It contains prazosin 0.5mg and Hydrochlorothiazide 12.5mg.

  • Description

Description

Miniplus is a brand of antihypertensive (prazosin Hydrochloride and Hydrochlorothiazide in combination). It contains prazosin 0.5mg and Hydrochlorothiazide 12.5mg.

Indication:

  • Management of moderate hypertension
  • The prazosin component in Miniplus affords an added advantage of symptomatic improvement of co-morbidity with Benign Prostatic Hyperplasia (BPH).

Prazosin acts by binding to specific alpha-1 receptors, displacing the binding of Norepinephrine post-synaptically while Hydrochlorothiazide impairs sodium re-absorption into the distal tubules.

These actions cause a reduction in Total Peripheral Vascular Resistance (TPVR) and an increased excretion of salt and water.

FEATURES BENEDICTS
Prazosin is a specific alpha-1 blocker. Does not compromise circulatory dynamics.
Locally manufactured. Readily available.
Fixed dose combination. Good safety profile.
Hydrochlorothiazide causes sodium excretion. Ideal for the black hypertensive
Cost-effective. Affordable.

 

Dosage: 1 tablet twice daily. Dosage may be increased to 2 twice daily to get desired results.

…. The antihypertensive tailored for the black patient.